Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Start Training Now
IAPAM Logo
Aesthetic Medicine Symposium - September 18-21 in Scottsdale, AZ! Secure Your Spot

Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification

IAPAM Logo
Aesthetic Medicine Symposium - September 18-21, Scottsdale, AZ! Secure Your Spot
Home » Medical Weight Management Library GLP-1 Agonists: A Quick Guide

GLP-1 Agonists: A Quick Guide

Empowering Medical Aesthetic Clinics, Practitioners, and Patients

Glucagon-like peptide‑1 (GLP‑1) receptor agonists have transformed Type 2 diabetes care and reshaped evidence‑based weight‑management programs. First approved in 2005, these medicines help lower blood glucose, reduce appetite, and can support clinically meaningful weight loss. Most are given by subcutaneous injection into the abdomen, thigh, or upper arm; one option is available as a daily tablet.

GLP‑1 agonists
As labeling and indications continue to evolve, it’s essential for clinics and consumers to understand how the class works, who it’s for, and how to navigate individual products.

Key Takeaways

  • What they do: GLP‑1 agonists stimulate glucose‑dependent insulin release, suppress glucagon, slow gastric emptying, and increase satiety—lowering A1C and often reducing weight. They complement, not replace, nutrition, activity, sleep, and behavior change.
  • Who they’re for: Core indications include Type 2 diabetes; select GLP‑1 products and related agents are approved for chronic weight management. Choice depends on goals (A1C, weight, cardiovascular/renal risk), tolerability, device preference, and access.
  • Options today: Weekly injectables such as Ozempic® (semaglutide) and Trulicity® (dulaglutide); daily injectables such as Victoza® (liraglutide); an oral GLP‑1, Rybelsus® (semaglutide); and the dual GLP‑1/GIP agonist class (Mounjaro®/Zepbound®; tirzepatide). Efficacy, indications, and labels differ meaningfully—always verify current prescribing information.
  • Safety first: Common GI effects are dose‑related and typically transient; serious risks are uncommon. Screen for contraindications (e.g., personal/family history of MTC/MEN2), pancreatitis history, gallbladder disease, significant GI motility disorders, and pregnancy. Counsel on retinopathy risk when A1C falls rapidly (especially with pre‑existing retinopathy) and on hypoglycemia risk when combined with insulin or sulfonylureas.

What are GLP‑1 Agonists?

  • A medication class for Type 2 diabetes (T2D) that mimics the body’s GLP‑1 hormone.
  • Several agents (or their higher‑dose counterparts) are approved for chronic weight management in eligible people with obesity, or overweight plus weight‑related comorbidity.
  • Administration: mostly subcutaneous injections (weekly or daily); one oral option (Rybelsus®) is a daily tablet.
  • These therapies are adjuncts to, not substitutes for, lifestyle interventions.
Reserve Your Spot
AN IAPAM TRAINING | September 18-21, 2026 | Limited Time Offer: Save 15% on registration
Gain the confidence you need — build the lifestyle & practice you deserve

Includes hands-on Botox® injection training on live models in a clean clinic setting

33.5 CMES | 4-Day Hands-On | Scottsdale, Arizona | Save up to $3,605
AN IAPAM TRAINING | September 18-21 | Save 15% on Registration
Gain the confidence you need — build the lifestyle and practice you deserve
33.5 CMEs | 4-Day Hands-On | Scottsdale, Arizona | Save up to $3,605
Reserve Your Spot

How GLP‑1 Agonists Work (in brief)

GLP-1 Agonists – Mechanisms by System
GLP‑1 Agonists: Mechanisms by Organ/System
Organ/System Primary Effects
Pancreas
  • Increase glucose‑dependent insulin secretion
  • Lower post‑meal and fasting glucose
Liver Suppress glucagon to reduce hepatic glucose output
Gut Slow gastric emptying, blunting post‑prandial glucose excursions
Brain Enhance satiety and reduce appetite, often decreasing caloric intake
Dosing considerations Higher doses typically yield greater A1C and weight effects, balanced against tolerability

When are GLP‑1 Agonists Used?

  • Type 2 diabetes
    • Consider when metformin is insufficient or contraindicated, when A1C remains above target, or when ASCVD/CKD risk reduction is a priority per guidelines and product labels.
    • Often combined with other glucose‑lowering agents; may allow de‑intensifying insulin or sulfonylureas to reduce hypoglycemia.
  • Chronic weight management
    • Specific GLP‑1 products (or related agents) are approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight‑related conditions; some have adolescent indications. Therapy is paired with nutrition, activity, sleep, and behavioral support.
  • Type 1 diabetes
    • Not FDA‑approved; any use is off‑label and specialist‑directed.

Available GLP‑1 (and related) Medications

GLP‑1 and Related Agents – Formulations and Schedules
GLP‑1 Agonists and Related Agents: Formulations and Schedules
Agent (Generic) Brand Example(s) Schedule / Route Notes
Dulaglutide Trulicity® Weekly, single‑use autoinjector GLP‑1 receptor agonist
Exenatide Byetta®; exenatide ER: Bydureon BCise® Byetta: twice‑daily injection; Bydureon BCise: weekly Immediate‑release and extended‑release options
Liraglutide Victoza®; higher‑dose liraglutide: Saxenda® Daily injection Some formulations indicated for weight management
Lixisenatide Adlyxin® Daily injection GLP‑1 receptor agonist
Semaglutide Ozempic® (inj.); Rybelsus® (oral); Wegovy® (inj.) Ozempic: weekly injection; Rybelsus: daily tablet; Wegovy: weekly injection Higher‑dose formulations indicated for weight management and additional labeled indications
Tirzepatide (dual GLP‑1/GIP RA) Mounjaro®; higher‑dose: Zepbound® Weekly injection Mounjaro for T2D; Zepbound for weight loss and additional labeled indications
Note: Labels, indications, dosing, and safety information evolve. Always verify current product labeling and guidelines in your region.

Dosing Frequency, Routes, and Devices (general)

  • Weekly: Trulicity®, Ozempic®, Bydureon BCise®, Mounjaro®, Wegovy®, Zepbound®
  • Daily: Victoza®, Saxenda®, Adlyxin®; Rybelsus® (oral)
  • Twice daily: Byetta®
  • Clinic teaching points: Choose a consistent injection day; rotate sites; store and handle per label; understand missed‑dose rules.

Benefits Beyond Glucose Lowering (product‑specific and label‑dependent)

  • Weight reduction: common class effect; magnitude varies by agent and dose.
  • Cardiovascular outcomes: several agents (e.g., Ozempic®, Trulicity®, Victoza®) demonstrate reduced MACE in indicated adults with T2D and established CVD; Wegovy® has labeled MACE risk‑reduction in select adults with CVD and elevated body weight. Verify current labels.
  • Renal outcomes: evidence is evolving; some products have labeled data on slowing kidney disease progression in specific populations. Verify current prescribing information.

Common Side Effects and Key Risks

GLP‑1 Agonists – Safety and Side Effects
GLP‑1 Agonists: Safety, Side Effects, and Counseling Points
Category Details / Counseling Points
Common GI effects (dose‑related)
  • Nausea, vomiting, diarrhea, constipation
  • Often improve with gradual titration and dietary adjustments
Other common effects Decreased appetite, dyspepsia, headache, mild dizziness, mild injection‑site reactions
Hypoglycemia risk Low when used alone; risk increases with insulin or sulfonylureas—consider dose adjustments of those agents
Pancreatitis and gallbladder disease Rare but important; educate on warning symptoms such as persistent severe abdominal pain or jaundice
Retinopathy Rapid glycemic improvement can transiently worsen pre‑existing retinopathy; coordinate eye care
Boxed warning (class) Risk of thyroid C‑cell tumors in rodents; contraindicated with personal/family history of MTC or MEN2
Pregnancy Generally not recommended; plan contraception and preconception counseling
Allergy / antibodies Rare systemic reactions; exenatide has higher rates of anti‑drug antibodies—monitor efficacy and injection‑site reactions

How to Choose Among Prominent Options

  • Ozempic® (semaglutide, weekly injection; multidose pen)
    • For T2D; labeled cardiovascular risk reduction in adults with established CVD. Evidence of meaningful weight loss; label and access differ from Wegovy® (semaglutide for weight management).
    • Practical: Dial‑a‑dose pen; start low, titrate to 0.5–2 mg weekly as needed and tolerated.
  • Rybelsus® (oral semaglutide, daily)
    • For T2D; only oral GLP‑1 option. Take on empty stomach with ≤4 oz water; wait 30 minutes before food/other meds.
    • Consider when injections are a barrier; titration and maximum effective dose differ from injectable semaglutide.
  • Wegovy® (semaglutide, weekly)
    • For chronic weight management in eligible adults and adolescents; also labeled to reduce MACE risk in select adults with CVD and elevated body weight. Additional indications may exist; verify current label.
    • Not for treating diabetes; dosing escalates to higher maintenance than Ozempic®.
  • Trulicity® (dulaglutide, weekly single‑use autoinjector)
    • For T2D in adults and children ≥10; labeled cardiovascular benefit in appropriate adults. Weight loss can occur.
    • Device simplicity benefits needle‑averse or dexterity‑limited patients; titration up to 4.5 mg weekly.
  • Victoza® (liraglutide, daily)
    • For T2D in adults and children ≥10; labeled cardiovascular benefit in adults with established CVD. Modest weight loss; lower‑cost generic exists in some markets.
  • Saxenda® (liraglutide, daily; higher dose)
    • For chronic weight management in eligible adults and adolescents. Greater injection frequency than weekly agents; weight loss typically less than with higher‑dose semaglutide or tirzepatide.
  • Byetta® (exenatide, twice daily) and Bydureon BCise® (exenatide ER, weekly)
    • For T2D (Byetta adults; Bydureon BCise ≥10 years). Useful for post‑prandial spikes (Byetta).
    • No labeled CV risk reduction; generics may lower cost.
  • Mounjaro® (tirzepatide, weekly; dual GLP‑1/GIP)
    • For T2D; head‑to‑head trials show larger A1C and weight reductions vs semaglutide 1 mg in some studies.
    • CV outcomes labeling may evolve; verify current status.
  • Zepbound® (tirzepatide, weekly; higher dose)
    • For chronic weight management in eligible adults; also approved for moderate‑to‑severe OSA in people with elevated body weight.
    • Trials show substantial average weight loss; compare access and coverage to Wegovy®.

Where Trulicity® and Ozempic® Often Diverge in Practice

  • Efficacy: Ozempic® generally yields greater average A1C and weight reduction at therapeutic doses; Trulicity® delivers strong glucose control with a highly user‑friendly single‑use autoinjector.
  • Cardiometabolic protection: both have labeled CV benefits in indicated adults with T2D and established CVD; renal data are evolving and differ by product.
  • User experience: Trulicity®’s hidden‑needle, single‑use pen simplifies steps; Ozempic® requires pen needles and dose dialing but offers broader dose ranges.
  • Access: coverage and availability vary; align choice with insurance, supply, and patient preference via shared decision‑making.

Clinic Playbook: Starting, Titrating, and Supporting Patients

  • Start low, go slow
    • Set expectations on GI effects; escalate doses every ~4 weeks if tolerated.
    • Provide a GI toolkit: smaller low‑fat meals, protein prioritization, hydration, fiber, ginger/peppermint; pause titration during persistent nausea.
  • Safety screen
    • Contraindications (e.g., MTC/MEN2), pregnancy plans, pancreatitis/gallbladder history, severe gastroparesis, significant retinopathy, renal risk, concurrent insulin/sulfonylurea.
  • Coordination and follow‑up
    • Check‑ins at ~weeks 2, 6, and 10 during titration; lab review and plan adjustment by ~12 weeks.
    • Align with primary care/endocrinology for A1C, kidney function, lipids, and eye care.
  • Education and expectations
    • Weight loss is gradual and plateaus are normal. Continuation sustains benefits; stopping often reverses gains.
    • For people with T2D on insulin/sulfonylureas, consider down‑titration to reduce hypoglycemia risk as the GLP‑1 effect emerges.
  • Devices and technique
    • Demonstrate pen setup (needle attachment for Ozempic®, etc.; single‑use mechanism for Trulicity®, Wegovy®, Mounjaro®, Zepbound®). Review site rotation and sharps disposal. For Rybelsus®, rehearse the morning timing routine.

Frequently Asked Questions

  • Can GLP‑1 agonists cause hypoglycemia? Alone, the risk is low because action is glucose‑dependent. The risk increases when combined with insulin or sulfonylureas—your clinician may lower those doses.
  • Do I qualify for a weight‑management GLP‑1? It depends on BMI, weight‑related conditions, age, and local labeling. Products, doses, and indications differ from T2D‑only versions.
  • Are these lifelong medicines? Benefits generally persist with ongoing use; stopping typically leads to partial or full return of prior weight and glycemia. Long‑term plans are individualized.
  • Can I switch agents? Yes, with a clinician‑directed cross‑titration plan, updated counseling, and close monitoring for tolerability and glycemic response.

Important Cautions

This overview is educational and non‑exhaustive. Labels, indications (including cardiovascular, renal, and liver‑related claims), and access programs change. Always consult current prescribing information and collaborate with a qualified clinician for personalized care. Peri‑procedural management should be aligned with current multi‑society guidance and anesthesia recommendations.

Conclusion

GLP‑1 therapies help many people with Type 2 diabetes reach A1C goals and support meaningful weight reduction, with additional cardiometabolic benefits in the right populations. Choosing among options—whether Ozempic®, Trulicity®, Rybelsus®, Wegovy®, Mounjaro®, Zepbound®, Victoza®, Saxenda®, Byetta®, Bydureon BCise®, or Adlyxin®—comes down to goals, safety, tolerability, device preference, and access. Pair medication with nutrition, movement, sleep, and behavioral support to turn early progress into durable health gains.
Disclaimer: The information provided here is for general knowledge only and should not be considered medical advice. For any questions or concerns about your health or medications, please consult your physician or healthcare provider. They are best equipped to provide guidance specific to your medical needs.

Related Articles

anatomy for botox injection sites

Essential Anatomy for Botox® Injection Sites

Botox® injections typically cause minimal discomfort, often described as a slight pinch or stinging sensation, comparable to a bug bite. To further minimize any discomfort, practitioners may use fine-gauge needles and can apply numbing cream to the treatment area before the procedure.

Read More »
Hands-On BOTOX® Training in Scottsdale, Arizona
Gain the Confidence to Start Seeing Patients Right Away!

Attend the most comprehensive accredited AMA PRA CAT 1 CME Botox® training weekend, learn how to create a profitable practice with the top 5 most lucrative non-invasive treatments.

Add-on GLP-1 agonists for weight loss and/or business for 4-days of comprehensive, fun CME-accredited training like none other! 

Hands-on Botox® Training for Physicians

Hands-on Botox® injection training is done in a clean multi-million dollar medspa, NOT in a hotel. We provide live models and product, you show up and enjoy the weekend with our expert instructors!

September 18-21, 2026

Scottsdale, Arizona 

Register Now

Save $3,605 when you become an IAPAM member and register to attend all 4-days!